PMS2P2
Putative postmeiotic segregation increased 2-like protein 2
Also known as: PM2P2_HUMAN
Protein identityUniProt · HPA
OverviewNCBI Gene
No narrative summary is available for PMS2P2 in this catalog release; identity and structured annotations are shown without generated factual claims.
Canonical amino-acid sequenceUniProt
297 residues, UniProt reviewed canonical sequence.
>O95744|PMS2P2
1 MGESSRKPPT PTPEGPTVSV KQLFSTLPVR HKEFQRNIKK KRACFPFAFC RDCQFLEGSP
61 AMLPVQPAKL TEPAKAIKPI DRKSVHQICS GPVVLSLSTA VKKIVGNSLD AGATNIDLKL
121 KDYGMDLIEV SGNGCGVEEE NFEGLSLSAL KHHTSKIREF ADLTRVETFG FQGKALSSLC
181 ALSDVTISTC HVSAKVGTRL VFDHDGKIIK KTPYPHPRGT TVSVKQLFST LPVRHKEFQR
241 NIKKKRACFP FAFCRDCQFL EGSPAMLPVQ PAKLTVTGEL RACRSWKTRE GITEAVGLocalizationUniProt · AlphaFold · HPA
Whether an antibody against PMS2P2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.4
OntologyGO
Biological processes
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads PMS2P2 as an antibody target. Whether an autoantibody or antibody against PMS2P2 could matter depends on whether native PMS2P2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
PMS2P2 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label PMS2P2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...